Kornimate/medical-research-clean huggingface dataset:
orthopaedic simulation of morton's extension to test the effect on plantar pressures of each metatarsal head in patients without deformity: a pre-post-test study.

Conditions: Healthy Subjects

Summary: the aim of this study is to simulate the orthopedic treatment called morton's extension on non-deformed patients to check the effects on each metatarsal head on its static footprint.

the objective of this study is to perform an assimilation of the orthopedic treatment called morton extension on non-deformed patients to verify the effects on each metatarsal head on its static footprint, specifically the mean pressures and before and after the application of the morton extension.

Eligibility criteria:
inclusion criteria: * no history of trauma to the foot; * the presence of at least 10° of dorsiflexion at the ankle with the knee fully dorsiflexed; * unrestricted motion of the functional subtalar joint of 30°; * unrestricted motion along the longitudinal axis of the midtarsal joint of 15°; * unrestricted nonweight-bearing motion of the first ray of at least 8 mm; * greater than 50° of dorsiflexion of the hallux to the first metatarsal bisection during nonweight-bearing; * age greater than 18 years and younger than 60 years; * at the time of data collection, no lower limb dysfunction or chronic injury; and * no evidence of a non-fixed deformity at first mtp and first metatarsal cuneiform joints. exclusion criteria: * plantar corns and calluses, * hallux valgus and lesser toe deformities, * diabetes, * any abnormality in the lower extremity that may affect gait.

Keywords: metatarsalgia foot orthopedics
comparison between asynchronous online care model with usual in office care for the management of atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine if an asynchronous online model of teledermatology can achieve similar clinical outcomes as compared to conventional in-office care for the management of atopic dermatitis. the investigators also aim to determine the effects of this online care model on patient quality of life as well as patient and physician satisfaction. the investigators' hypotheses include the following: 1. compared to in-person visits, the online care model will result in similar clinical improvement in atopic dermatitis disease severity. 2. compared to in-person visits, the online care model will result in similar improvements in quality of life. 3. providers and subjects in the online group will achieve a similar level of overall satisfaction as those in the in-person group.


Eligibility criteria:
inclusion criteria: * patients aged 4 years or older at time of consent, may be male or female. * meet the hanifin diagnostic criteria for atopic dermatitis. * capable of giving informed consent (for patients less than 18 years of age, assent will be obtained from the minor and informed consent will be obtained from a legal guardian). * able to image their skin or have someone do it for them. * able to adhere to the study visit schedule and other protocol requirements. * have access to a computer with internet connection, a digital camera, and an e-mail address. exclusion criteria: * non english speaking patients. * patients requiring systemic treatment (e.g., cyclosporine, phototherapy). * patients requiring close laboratory monitoring.

Keywords: teledermatology telemedicine atopic dermatitis
using continuous glucose monitoring to detect and intervene on maintenance factors for trans-diagnostic binge eating pathology

Conditions: Bulimia Nervosa; Binge Eating

Summary: the current study will be one of the first to develop and test a passive data collection technique to detect both meal consumption and disordered eating symptoms in patients with clinically significant binge eating and the first just-in-time adaptive interventions (jitais) systems using passive sensing technology for eating pathology to be empirically evaluated. a small iterative open clinical trial using an abab design (a= sensesupport off, b=sensesupport on) will be conducted to test the feasibility, acceptability, and target engagement of sensesupport when paired with a 12 week in-person cbt treatment program. the hypothesis that larger decreases in dietary restriction will be observed during sensesupport on phases compared to sensesupport off phases will be tested in this clinical trial.


Eligibility criteria:
inclusion criteria: * are 18 to 65 years old * experience clinically significant binge eating (defined as 12 or more objectively large binge eating episodes in the past 3 months) * engage in clinically significant dietary restriction (define as \>1 standard deviation above community norms on the eating disorder examination dietary restraint subscale) * have a bmi above 18.5 * are able to give consent exclusion criteria: * are unable to fluently speak, write and read english * are receiving treatment for an eating disorder * require immediate treatment for medical complications as a result of eating disorder symptoms * have a mental handicap, or are experiencing other severe psychopathology that would limit the participants' ability to comply with the demands of the current study (e.g. severe depression with suicidal intent, active psychotic disorder) * have diabetes * are pregnant or planning to become pregnant within the next year
e-health tool for management of chronic pain patients.

Conditions: Chronic Pain

Summary: chronic pain affects approximately 20% of adults, 50% of the elderly population and over 1.5 billion people worldwide. societal and economic issues are also crucial, as 60% of people with pain are less able or unable to work and 20% say they have lost their jobs because of pain. the overall cost of chronic pain is estimated at around 300 billion euros in the eu. unfortunately, current treatments for chronic pain have limited effectiveness. pain clinics, which support the most complex and refractory cases of chronic pain, as well as general practitioners and patients expect improvements, both in terms of therapeutic efficacy and organization of care. in order to allow the characterization and a personalized follow-up of chronic pain patients, investigator has created e-dol, a smartphone application for patients and a web platform for physicians. the purpose of this study is to evaluate the feasibility and clinical interest of an e-health smartphone application for the characterization and follow-up of chronic pain patients..

this first clinical study will assess the acceptability of the tool both by caregivers at the 13 pain clinics and by a panel of 300 patients followed for 6 months. based on the results of the study (end 2019), investigator will improve the tool in a version 2.0, which will then be evaluated in a large impact study, measuring the intrinsic therapeutic effect of edol.

Eligibility criteria:
inclusion criteria: * all patients with chronic pain * patients with and regular users of a smartphone * non-opposition to participation in the study exclusion criteria: * patient unable to understand or answer questionnaires

Keywords: chronic pain e-health
microvascular invasion artificial intelligence prediction via contrast-enhanced ultrasound with explainability

Conditions: HCC - Hepatocellular Carcinoma; Microvascular Invasion (MVI)

Summary: an artificial intelligence (ai) model to predict mvi of hcc using contrast-enhanced ultrasound was constructed. this model also has biological explainability. the investigators named it as mapuse (mvi ai prediction via contrast-enhanced ultrasound with explainability). the goal of mapuse study is to prospectively test the performance of mapuse model on mvi prediction and its biological correlation in different geographical areas of china.

the presence of microvascular invasion (mvi) in hepatocellular carcinoma (hcc) is a critical prognostic indicator, but its preoperative diagnosis remains challenging. contrast-enhanced ultrasound (ceus), with its dynamic microvascular imaging capability, holds promise in prediction of mvi. the investigators constructed an artificial intelligence (ai) model to predict mvi using contrast-enhanced ultrasound. this model also has biological explainability. we named it as mapuse (mvi ai prediction via contrast-enhanced ultrasound with explainability). the goal of mapuse study is to prospectively test the performance of mapuse model on mvi prediction and its biological correlation in different geographical areas of china. the performance of mapuse is to be tested in two prospective testing cohorts from two centers in southern and northern china. before surgery, patient ceus videos will be collected and analysed by mapuse model to generate an mvi risk score. according to the postoperative pathological diagnosis of mvi (golden criterion), the result of mapuse will be evaluated. parameters include area under curve (auc), accuracy (acc), sensitivity, specificity and f1-score.

Eligibility criteria:
inclusion criteria: 1. age \>18 years old. 2. the hcc diagnosis and the presence of mvi were confirmed by surgical pathology. 3. complete and clear ceus videos obtained within two weeks preoperatively. exclusion criteria: 1. unqualified ceus images. 2. missing surgical pathological diagnosis. 3. lesions underwent local treatments. 4. non-hcc diagnosis

Keywords: hepatocellular carcinoma microvascular invasion contrast-enhanced ultrasound deep learning
ledipasvir/sofosbuvir fixed-dose combination with ribavirin or gs-9669 in subjects with chronic genotype 1 hcv infection

Conditions: Chronic HCV Infection

Summary: this study will evaluate the antiviral efficacy of ledipasvir/sofosbuvir (ldv/sof) fixed-dose combination (fdc) plus ribavirin (rbv) or ldv/sof plus gs-9669 in treatment-naive or treatment-experienced participants with chronic genotype 1 hepatitis c virus (hcv) infection. a total of 90 participants are planned to be enrolled in the study for 8 weeks of treatment, approximately 60 having had prior treatment with a regimen containing pegylated interferon (peg) and rbv for ≥ 12 weeks. randomization will be stratified by treatment-naive versus treatment-experienced and by hcv genotype (1a versus 1b).


Eligibility criteria:
inclusion criteria: * age ≥ 18, with chronic genotype 1 hcv infection * documented hcv treatment-naïve or treatment-experienced subjects who failed previous peg+rbv regimen * hcv rna \> 10,000 iu/ml at screening * presence of compensated cirrhosis * screening laboratory values within defined thresholds * use of two effective contraception methods if female of childbearing potential or sexually active male exclusion criteria: * pregnant or nursing female or male with pregnant female partner * co-infection with hiv or hepatitis b virus (hbv) * current or prior history of clinical hepatic decompensation * chronic use of systemic immunosuppressive agents * history of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

Keywords: hcv genotype 1 hcv sustained virologic response direct-acting antiviral combination therapy gs-7977 gs-5885 ribavirin open label sofosbuvir treatment-naive protease inhibitors pi treatment experienced cirrhotic
long-term follow-up study of early stage breast cancer patients included in geicam studies

Conditions: Invasive Breast Cancer Early Stages

Summary: this is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the geicam group. patients will be included in this study from the moment of completion of the follow-up of the studies of origin and will be followed for approximately 30 years

one consequence of the improvement in survival rates of certain tumors such as breast cancer is the increase in the number of patients available for long-term follow-up in randomized controlled clinical trials. this long follow-up allows an additional long-term evaluation of the efficacy, as well as of the sequelae related to the treatments that may occur beyond the time of the primary analysis. the target population of the study are all patients who were included in neoadjuvant and adjuvant clinical trials of geicam performed by the goup since 1998 in the medical oncology units of the participating sites, ensuring a follow-up of patients of approximately 30 years. this will allow to describe the long-term evolution of the patients with invasive breast cancer in early stages. the information obtained will be very useful to professionals involved in the diagnosis, treatment and monitoring of breast cancer, hospital managers, patients with this condition and society in general. this study provides data of great interest for the estimation of long-term disease requirements.

Eligibility criteria:
inclusion criteria: * patients included in neoadjuvant and adjuvant clinical trials with geicam's participation. if any of these patients had taken part or is participating in another clinical trial, she/he is eligible for this trial and her/his information will also be collected. * patients whose death or contact loss has not been previously collected in the databases of the original studies. exclusion criteria: * patient who were not included in the analyses of the original studies due to non-compliance of the eligibility criteria or the original study informed consent withdrawal.

Keywords: long-term follow-up invasive breast cancer early stages previous neoadjuvant treatment previous adjuvant treatment
electrical impedance tomography for quantification of pulmonary edema in acute respiratory distress syndrome patients

Conditions: Acute Respiratory Distress Syndrome

Summary: evaluation of pulmonary edema is a key factor in monitoring and guidance of therapy in acute respiratory distress syndrome (ards) patients. to date, methods available at the bedside for estimating the physiologic correlate of pulmonary edema, extravascular lung water(evlw), often are unreliable or require invasive measurements. the purpose of the this study is to develop a novel approach to reliably assess extravascular lung water by electrical impedance tomography(eit).


Eligibility criteria:
inclusion criteria: patients will be included in this study if the following criteria have been met: 1. males and females \> 18 years old and \<85 years old (non-pregnant, non-lactating females). 2. patients fulfilled the berlin diagnostic criteria of ards 3. signed written informed consent has been obtained 4. patients had monitoring system pulse-induced contour cardiac output (picco) exclusion criteria: 1. females who are pregnant or lactating. 2. patients with contraindication of eit(skin abrasions or wounds in the chest area.patients with pacemakers or paced ekg rhythms.thoracic deformity. severe subcutaneous emphysema) 3. patients \ 85 years old 4. patients without monitoring system pulse-induced contour cardiac output (picco) 5. patients with cardiac function of grade 4 or patients with acute myocardial infarction or acute coronary syndrome
trial on profermin and fresubin in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this study aim to investigate the effect of profermin versus fresubin in the dietetic treatment of active ulcerative colitis.


Eligibility criteria:
inclusion criteria: * active ulcerative colitis (sccai =\>5 and \<=11) * access to internet exclusion criteria: * stoma or intestinal resections * recent changes in uc medication * treatment with antibiotics * diabetes * celiac disease * lactose malabsorption

Keywords: ibd uc profermin fresubin probiotics dietetic
dopamine versus norepinephrine under general anesthesia

Conditions: Anesthesia; Infant; Congenital Heart Disease; Hemodynamic Instability

Summary: participants under general anesthesia will be randomly treated with an adjusted dose dopamine or norepinephrine to elevate 10% of mean arterial pressure. systemic hemodynamic data is recorded by pram and the change of cardiac index is compared between groups.

after intubation under general anesthesia, radial arterial is cannulated and pressure transducer is connected to mostcare(core technique pram). ci, svri, svi, svv, dp/dt and hr are recorded before and after a infusion of dopamine or norepinephrine to elevate 10% of mean arterial pressure. changes of these hemodynamic data are compared.

Eligibility criteria:
inclusion criteria: * undertake cardiac surgery for congenital heart disease exclusion criteria: * aortic valve or aortic disease * severe arrhythmia * use of cardiovascular active drugs before anesthesia * need to use a combination of different cardiovascular support drugs after anesthesia

Keywords: norepinephrine dopamine
mucolytic solution before upper endoscopy

Conditions: Gastroscopy; Gastric Cancer

Summary: study was designed to evaluate efficacy of mucolytic solution ingested before upper endoscopy on visibility of gastric mucosa.

residual gastric content containing mucus, bubbles, bile and food particles may limit visibility of gastric mucosa and therefore diagnostic yield of upper endoscopy, especially in cases of early neoplastic lesions. data on benefit of peroral mucolytic solution administered before upper endoscopy are limited.

Eligibility criteria:
inclusion criteria: * age \> 18 years * signed informed consent * diagnostic gastroscopy exclusion criteria: * age \< 18 years * interventional gastroscopy * known disease of the upper gi tract and/or history of surgery of gi tract * gastroscopy indicated of bleeding, dysphagia or ileus * liver cirrhosis * general anesthesia
livacor trial: minimally invasive liver and simultaneous colorectal resection

Conditions: Colorectal Neoplasms Malignant; Neoplasm Metastasis

Summary: the livacor - trial is a european wide, randomized controlled, open-label, multicenter trial. patients with synchronous colorectal liver metastases (crlms) and primary colorectal tumor are considered eligible and will be randomized between minimally invasive (mi) combined or staged colorectal resection (all colectomies, including high anterior resection) and liver resection of up to three segments.


Eligibility criteria:
inclusion criteria: * ≥ 18 years * diagnosed with primary crc with resectable synchronous crlms (with or without neoadjuvant chemotherapy)\* * elective indication for mi combined or staged colorectal resection (all colectomies, including high anterior resection) and liver resection of up to 3 segments with a maximum of 2 separate liver resections. the mi two-staged approach includes both the conventional strategy (first resection of primary colorectal tumor followed by liver resection for crlms) and liver-first strategy (first crlms resection followed by resection of colorectal primary tumor). patients undergoing bilobar resections are eligible (if 3 or fewer segments are resected) * bmi between and including 18-35 * patients with american society of anesthesiologists (asa) physical status i-iii and the american college of surgeons national surgical quality improvement project (acs nsqip) universal surgical risk score of ≤ 50% for serious complications * in case of neoadjuvant chemotherapy, time interval between last chemotherapy cycle and (first) surgery should be 4-6 weeks. exclusion criteria: * inability to give (written) informed consent. * patients requiring a planned temporarily or permanent stoma after colorectal resection (all colectomies, including high anterior resection). patients who will receive an unplanned stoma intraoperatively, will be analysed according to their initial treatment assignment. * patients requiring multivisceral colorectal resection (all colectomies, including high anterior resection). * indication for mi combined or staged low anterior resection, total mesorectal excision or abdominoperineal resection and liver resection of four or more segments (i.e., hemihepatectomy or more extensive resections). * patients with peritoneal metastases. * patients with asa physical status iv-v and acs nsqip surgical risk score of \> 50% for serious complications. * repeat open hepatectomy * surgical history of colorectal- or liver resection for neoplastic disease * surgical history of major or complicated open abdominal surgery * indication for concurrent thermal ablation * medical history of thermal ablation of liver for malignancy * unresectable extrahepatic metastases * pre-operatively reconstruction of vessels/bile ducts is deemed necessary
scapular stabilization exercises versus eccentric muscle energy techniques in patients with upper crossed syndrome

Conditions: Upper Crossed Syndrome

Summary: this study will be a randomized clinical trial in which scapular stabilization exercises and eccentric muscle energy technique will be applied on the individuals with upper crossed syndrome and changes will be recorded using different method and tools. convenient sampling technique will be used to collect the data. the sample size of 34 patients will be recruited. patients will be randomly allocated into two different groups through sealed envelope method. 17 patients will be allocated in each group. group a will be treated with scapular stabilization exercises along with hot pack; group b will be treated with eccentric muscle energy technique along with hot pack. craniovertebral angle (cva), numeric pain rating scale (nprs), and neck disability index (ndi) will be used as data collecting tools.

upper crossed syndrome is defined byjanda as the involvement of different muscles of skeletal system which leads to shortness and tightness of anterior and upper trunk or weakness of posterior part of skeletal muscles. alteration of muscles activity such as facilitation of different muscles as levator scapula, sternocleidomastoid, pectoralis muscles and inhibition of cervical flexors, serratus anterior the muscular imbalance occurs because of weak/tight and tonic muscles. neck pain is the most frequent problem in developed countries. the prevalence of neck pain is approximately 10-15%. neck pain is the most common reason for patients visiting healthcare professionals. poor posture typically causes upper cross syndrome (ucs), resulting in neck pain. this syndrome can cause dysfunctional tone in posture and muscular disparity of head, neck and shoulder region.

Eligibility criteria:
inclusion criteria: * • age: participants having range 18-35 years both male and female are included. * craniovertebral angle\<52 * nprs\>3 and ndi\>10 * patients having neck pain during movements. * patients having neck pain due to sustained posture and after activity exclusion criteria: * inflammation malignancy, neurological disorder * metabolic disorders * neck pain radiating into arms and upper extremity * neck pain associated with headache and facial pain * recent surgery * history of recent trauma and fractures of cervical spine * patients having any other therapeutic intervention or medical treatment.

Keywords: upper crossed syndrome, scapular stabilization exercises, eccentric muscle energy technique, pain, functional disability
characterization of the plasma proteome following left ventricular assist device implantation

Conditions: Ventricular Dysfunction, Left

Summary: the purpose of this study is to characterize changes in the plasma proteome over time following left ventricular assist device (lvad) implantation.


Eligibility criteria:
inclusion criteria: * planned heartmate ii lvad implantation * planned warfarin (goal inr, 2.0-3.0) and low-dose aspirin therapy post-lvad placement exclusion criteria: * prior history of mechanical circulatory support; * body weight \< 110 lbs; * pre-existing hemolytic, bleeding, or immunologic disorders prior to lvad implantation; * severe aortic stenosis; * renal failure requiring dialysis; * hepatic dysfunction resulting in severe coagulopathies; * recent serious infection; * current need for prolonged ventilatory support; * prior organ transplantation; * blood transfusion within 14 days of the first planned study blood draw; * concomitant immunosuppressant or chemotherapeutic agents; * pregnant women; * decisionally challenged or prisoners; * unwilling to provide written informed consent